OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
200580.KN56

Medyssey Co Ltd

Medical Equipment, Supplies & DistributionVerified

Capital Structure and Liquidity Medyssey maintains a strong liquidity position with a current ratio of 5.66, indicating a robust ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity risk. The debt-to-equity ratio of 0.06 suggests a conservative capital structure with minimal leverage. ### Profitability and Returns The company's return on equity (ROE) of 8.83% and return on assets (ROA) of 7.38% indicate solid profitability relative to its equity and asset base. These metrics suggest that Medyssey is effectively utilizing its capital to generate returns, though a direct comparison to industry medians is required to assess relative performance. ### Segments and Geographic Exposure Medyssey's revenue is concentrated in spinal implant products, with additional offerings in fixation devices for thoracic and orthopedic surgeries. The company's geographic exposure is primarily within South Korea, with no disclosed international revenue segments. This concentration may limit diversification benefits and increase vulnerability to domestic market fluctuations. ### Growth Trajectory The company's revenue growth trajectory is not explicitly provided, but its strong operating cash flow of KRW 3.46 billion and free cash flow of KRW 1.66 billion suggest a capacity for reinvestment and expansion. The capital expenditure of -KRW 3.04 billion indicates a net outflow, potentially signaling investment in new facilities or equipment. ### Risk Factors The primary risk for Medyssey is liquidity, as highlighted by the negative net cash position after debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. No recent events or filings have been disclosed that would significantly alter the company's risk profile. ### Recent Events No recent events, filings, or transcripts have been disclosed that would significantly impact Medyssey's operations or financial position.

30-day price · 200580.KN-210.00 (-1.8%)
Low$10990.00High$12990.00Close$11790.00As of15 May, 00:00 UTC
Profile
CompanyMedyssey Co Ltd
Ticker200580.KN
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Medyssey Co Ltd is a Korea-based company engaged in the manufacture and sale of orthopedic spinal implants, fixation devices for pectus excavatum, and orthopedic implants for bow-leg correction.

Classification. Medyssey is classified under the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution industry, with a confidence level of 0.92.

### Capital Structure and Liquidity Medyssey maintains a strong liquidity position with a current ratio of 5.66, indicating a robust ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity risk. The debt-to-equity ratio of 0.06 suggests a conservative capital structure with minimal leverage. ### Profitability and Returns The company's return on equity (ROE) of 8.83% and return on assets (ROA) of 7.38% indicate solid profitability relative to its equity and asset base. These metrics suggest that Medyssey is effectively utilizing its capital to generate returns, though a direct comparison to industry medians is required to assess relative performance. ### Segments and Geographic Exposure Medyssey's revenue is concentrated in spinal implant products, with additional offerings in fixation devices for thoracic and orthopedic surgeries. The company's geographic exposure is primarily within South Korea, with no disclosed international revenue segments. This concentration may limit diversification benefits and increase vulnerability to domestic market fluctuations. ### Growth Trajectory The company's revenue growth trajectory is not explicitly provided, but its strong operating cash flow of KRW 3.46 billion and free cash flow of KRW 1.66 billion suggest a capacity for reinvestment and expansion. The capital expenditure of -KRW 3.04 billion indicates a net outflow, potentially signaling investment in new facilities or equipment. ### Risk Factors The primary risk for Medyssey is liquidity, as highlighted by the negative net cash position after debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. No recent events or filings have been disclosed that would significantly alter the company's risk profile. ### Recent Events No recent events, filings, or transcripts have been disclosed that would significantly impact Medyssey's operations or financial position.
Key takeaways
  • Medyssey maintains a strong liquidity position with a current ratio of 5.66.
  • The company's ROE of 8.83% and ROA of 7.38% indicate solid profitability.
  • The debt-to-equity ratio of 0.06 suggests a conservative capital structure.
  • The company's revenue is concentrated in spinal implant products and South Korea.
  • The negative net cash position after debt highlights potential liquidity risk.
  • No significant dilution risk is identified, with low dilution potential.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$28.31B
Gross profit$18.97B
Operating income$3.95B
Net income$3.33B
R&D
SG&A
D&A
SBC
Operating cash flow$3.46B
CapEx-$3.04B
Free cash flow$1.66B
Total assets$45.10B
Total liabilities$7.41B
Total equity$37.70B
Cash & equivalents$2.24B
Long-term debt$2.40B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$37.70B
Net cash-$151.9M
Current ratio5.7
Debt/Equity0.1
ROA7.4%
ROE8.8%
Cash conversion1.0%
CapEx/Revenue-10.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric200580.KNActivity
Op margin14.0%13.3% medp25 5.9% · p75 13.5%top quartile
Net margin11.8%8.6% medp25 2.7% · p75 12.7%above median
Gross margin67.0%64.0% medp25 60.1% · p75 65.6%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-10.8%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity6.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 09:50 UTC#af8665d1
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 15:37 UTCJob: 1f0277c1